ABSTRACTS – ORAL PRESENTATIONS - AMCA, spol. s r.o.

UNCE 204013.
References
Stulc T., Sedo A.: Inhibition of multifunctional dipeptidyl peptidase-IV: Is there a risk of
oncological and immunological adverse effects? Diabetes Res Clin Pract. 88(2): 125-3,
2010
40. NONCLASSICAL CD16 + PERIPHERAL BLOOD MONOCYTES EXPRESS CD11C WITH
HIGH INTENSITY IN EARLY RHEUMATOID ARTHRITIS
Olga Kryštůfková, Heřman Mann, Hana Hulejová, Ladislav Šenolt, Jiří Vencovský
Institute of Rheumatology, Prague, Czech Republic and Dept. of Rheumatology,
1 st Faculty of Medicine, Charles University, Prague, Czech Republic, krys@revma.cz
Three populations of human monocytes have been described based on the relative
expression of surface markers CD14 and CD16, as classical (CM; CD14 + CD16 - ), nonclassical
(NCM; CD14 dim CD16 ++ ) and intermediate (IM; CD14 + CD16 +/++ ) [1]. NCM are
potent antigen presenting cells and producers of proinflammatory cytokines, with high
migratory ability and are involved in Fc mediated killing. They were enriched in peripheral
blood (PB) of patients with rheumatoid arthritis (RA) and correlated with disease activity
and titers of rheumatoid factor [2-5]. Response to therapy with methotrexate (MTX)
was associated with reduction of CD16 expression [4,5]. Higher expression of CD16 on
RA synovial fluid monocytes compared to PB and in RA synovium was reported. CD11c
expressed by human monocytes, is involved in clearance of immune complexes, plays
a role in antigen presentation and in production of proinflammatory cytokines. Higher
expression of CD11c on mononuclear blood cells (PBMC) in patients with RA, expansion
of CD11c positive inflammatory macrophages in RA synovium and a predictive role of
higher CD11c mRNA expression for response to TNFα blocking treatment in RA were
shown [6-8].
The aim of this study was to evaluate the expression of CD11c on monocyte
subpopulations in patients with early rheumatoid arthritis (ERA) and to compare them
to patients with osteoarthritis (OA). We also studied changes of CD11c expression after
three months of treatment.
Thirty one patients with Early Rheumatoid Arthritis (ERA) and 9 gender and age-matched
patients with osteoarthritis (OA) were included. Patients in the ERA cohort had symptom
duration < 6 months and either fulfilled the 2010 ACR/EULAR classification criteria for RA
or had undifferentiated inflammatory arthritis. Serum CRP and anti-CCP autoantibody
levels and rheumatoid factor positivity were recorded. Disease activity was assessed
using DAS28.
Monocytes were selected using a sequential gating approach by exclusion of doublets
(high FSc Area plotted in versus FSc Lin), granulocytes (SSc high granular events), CD45 -
events and HLADR - /CD3 + /CD19 + lymphocytes. Their subpopulations were defined
based on the positivity of CD14 and CD16 according to IUIS nomenclature [1]. Classical
monocytes were defined as CD14 + CD16 - and non-classical as CD14 dim CD16 ++ . With use of
Analytical Cytometry VII 59